Sapience Therapeutics, Inc.
2 Overhill Road
Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme (GBM), which is the most severe and deadly form of brain cancer.
CEO: Barry Kappel, Ph.D., MBA
Chairman: Howard Pien
Please click here for clinical trial information.